First Biotherapeutics (CEO Jae-eun Kim, hereinafter referred to as First Bio) announced that it attended the opening ceremony of the Technology Credit Guarantee Fund Singapore branch held in Singapore on June 19 and introduced its main pipeline and global business strategy to local investors.
This event was co-hosted with Korea Venture Investment to commemorate the opening of the first overseas branch established by the Technology Guarantee Fund, and was prepared with the aim of supporting promising domestic venture companies to expand overseas and attract global venture capital (VC) investment.
FirstBio is the only new drug development company among the six invited companies, and introduced its main pipeline, including the immunotherapy candidate 'FB849' and degenerative brain disease treatment, as well as its technological differentiation, and cases of strategic collaboration with LigaChem Biosciences, the Michael J. Fox Foundation (MJFF), and MSD, to about 100 local investors and bio industry officials.
In addition, after the IR announcement, we held 1:1 meetings with Singapore-based investment firms and global VCs to discuss the possibility of actual investment and joint development.
First Bio was selected as a potential unicorn company in the 'Global Unicorn Project' hosted by the Ministry of SMEs and Startups in 2024, and is actively pursuing expansion into the global market based on its technological prowess and growth potential.
Kim Jae-eun, CEO of FirstBio, said, “This Singapore event was a meaningful opportunity to introduce FirstBio’s technological competitiveness and business potential to overseas investors,” and added, “We plan to use this as an opportunity to further accelerate global partnerships and commercialization.”
- See more related articles
You must be logged in to post a comment.